Pharmacokinetic and Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2016
Price : $35 *
At a glance
- Drugs Emixustat (Primary)
- Indications Age-related macular degeneration
- Focus Pharmacokinetics
- Sponsors Acucela
- 15 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 17 Jul 2015 Planned End Date changed from 1 Feb 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 17 Jul 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Sep 2015.